NAMZARIC Drug Profile, 2023: NAMZARIC (donepezil hydrochloride; memantine hydrochloride) drug patents, FDA exclusivity, litigation, drug prices

DrugPatentWatch

2023년 8월 · DrugPatentWatch.com

eBook 정보

<h2>NAMZARIC Drug Profile, 2023</h2>

<p>This report focuses on NAMZARIC and covers the following critical aspects of this drug:</p>

<ul><li>United States patents</li>

<li>Expired United States patents</li>

<li>FDA Paragraph IV patent challenges</li>

<li>District Court patent litigation</li>

<li>Patent Trial and Appeal Board (PTAB) patent cases</li>

<li>European supplementary protection certificates (SPCs)</li>

<li>Clinical trials</li>

<li>Drug prices</li>

<li>Finished product suppliers</li>

<li>Raw active pharmaceutical ingredient (API) sources</li>

</ul>